How Long Does SR9009 Stay in Your System? What the Literature Reports

What the Question Is Actually Asking

SR9009, often called stenabolic, is a synthetic small-molecule agonist of the REV-ERB nuclear receptors; a 2026 analytical study described it in exactly those terms while profiling its metabolites by LC-HRMS for anti-doping purposes (PMID 42530886). The first thing worth stating plainly is a category point: SR9009 is not a peptide. It is a small synthetic molecule, so the pharmacokinetic logic that governs peptides — peptidase cleavage, renal handling of small fragments, injection-site depots — does not transfer directly. Readers comparing compound classes may find the broader overview at how long peptides stay in your system useful as a contrast rather than as a template.

"How long does it stay in your system" is also four questions wearing one coat. Each has a different answer and a different quality of evidence behind it.

What the Verified Literature Does and Does Not Report on Half-Life

Across the papers verified for this page, no study reported a measured plasma half-life, oral bioavailability figure, or clearance rate for SR9009 in humans or in laboratory animals. That absence is itself the honest answer to the half-life query. Secondary sources sometimes circulate short half-life figures for SR9009; those numbers are not traceable to any paper in this citation set, so they are not repeated here. Where a page cannot support a number from a verified source, the number is omitted rather than paraphrased.

What the verified set does contain is metabolism-focused analytical chemistry. The 2026 study applied liquid chromatography–high-resolution mass spectrometry to profile SR9009 metabolites generated in camel liver homogenate and in cultures of the fungus Cunninghamella elegans, with the stated aim of supporting anti-doping analysis (PMID 42530886). Metabolite mapping of this kind answers "what is the molecule turned into, and what should an assay look for" rather than "how fast does the concentration fall." Those are complementary but distinct pharmacokinetic questions.

Why In Vitro and Microbial Models Are Used

Liver homogenate preparations and Cunninghamella elegans cultures are long-standing laboratory surrogates for mammalian phase I and phase II biotransformation, used when generating reference metabolites in living subjects is impractical. That is general analytical-chemistry background, not a finding of any single study. What the study itself contributed was the SR9009-specific metabolite profile obtained from those two systems (PMID 42530886). Models of this type do not produce half-life values, because they have no circulation, no renal filtration and no whole-body distribution volume.

Half-Life Versus Duration of Effect: Two Separate Clocks

REV-ERBα (gene name NR1D1) and REV-ERBβ are transcriptional repressors embedded in the molecular circadian clock. A compound that engages them changes gene expression programmes, and expression changes can outlast the presence of the compound that triggered them. This is why pharmacokinetics and pharmacodynamics diverge for nuclear-receptor ligands more than for, say, a short-acting analgesic.

Several verified papers illustrate how slow and rhythmic the underlying biology is. A 2023 study of the ARPE-19 retinal pigment epithelium line reported that induced senescence altered the circadian pattern of phagocytic activity in those cells (PMID 37027909). In a murine infection model, researchers reported that Rev-Erbα linked blue-light exposure with enhanced bacterial clearance and improved survival in Klebsiella pneumoniae pneumonia (PMID 31379019). A cardiac study reported that eliminating endogenous high-molecular-weight FGF2 prevented pressure-overload-induced systolic dysfunction, a change linked to increased FGFR1 activity and altered NR1D1 expression (PMID 34057573). None of these measured SR9009 washout; collectively they show that REV-ERB-linked outputs are measured in circadian cycles and tissue remodelling timescales rather than in minutes.

Time to Clearance: How the General Pharmacology Is Framed

In general pharmacokinetics — stated here as textbook principle, not as an SR9009 finding — a drug following first-order elimination falls to roughly 3% of its peak concentration after about five half-lives, and this is the conventional shorthand for "effectively cleared." Applying that arithmetic requires a half-life input. Because no verified paper here supplies one for SR9009, no clearance timeline can be stated for it without inventing the starting number.

Other general determinants of how long a small molecule persists include:

• Route and formulation — oral exposure is constrained by gut absorption and first-pass hepatic extraction, parenteral routes bypass both.
• Hepatic metabolic capacity — the enzymes performing oxidation and conjugation set the rate for most small molecules.
• Renal and biliary excretion — the exit routes for metabolites once they are formed.
• Protein binding and tissue distribution — a large distribution volume slows apparent elimination.
• Repeat exposure — accumulation occurs when dosing intervals are shorter than the elimination half-life.

These principles are generic. They are listed to show which variables would need measuring for SR9009, not to imply that anyone has measured them.

Detectability and Drug Testing: What Is and Is Not Screened

This is where the evidence is most concrete. The 2026 LC-HRMS study was explicitly framed around anti-doping analysis, generating SR9009 metabolite data in camel liver homogenate and Cunninghamella elegans so that laboratories have targets to screen for (PMID 42530886). Work of this type exists precisely because parent compounds are often poor markers — metabolites may persist longer and be more abundant in urine than the administered molecule.

Routine Clinical and Workplace Panels

Standard employment and clinical urine drug screens target a fixed list of substance classes — typically amphetamines, cannabinoids, cocaine metabolites, opiates and phencyclidine, with extended panels adding benzodiazepines, barbiturates, methadone and similar agents. SR9009 is not a member of any of those classes and is not an analyte on those panels. An immunoassay screen designed for opiates does not generate a signal for a REV-ERB agonist. Identifying SR9009 or its metabolites requires a purpose-built chromatographic-mass spectrometric method of the kind described in the anti-doping profiling study (PMID 42530886).

Sport Anti-Doping Context

As a regulatory fact rather than a study finding: REV-ERB agonists are named among metabolic modulators on the World Anti-Doping Agency Prohibited List, and equivalent rules apply in regulated animal-sport contexts, which is why metabolite reference data were generated in a camel liver model (PMID 42530886). SR9009 is not an approved medicine in the United States or the European Union and has no approved product label from which pharmacokinetic parameters could be read. Nothing in this section is legal advice.

What a Detection Window Would Require

A stated detection window needs three inputs: a validated assay, a known administered quantity, and timed biological samples from dosed subjects. The verified literature supplies progress on the first element for SR9009 (PMID 42530886) and nothing on the second or third. Any specific "detectable for X days" claim therefore has no support in this citation set.

Factors That Could Change Clearance

Liver health is the variable most directly touched by the verified papers. A 2025 expert review examined the regulation of cyclophosphamide-induced hepatotoxicity by REV-ERBα modifiers, placing REV-ERB pharmacology squarely in the context of hepatic injury and drug handling (PMID 40211567). Because the liver is both a REV-ERB-rich tissue and the principal site of small-molecule biotransformation, hepatic status is plausibly bidirectional here — a point the review raises conceptually rather than a measured clearance effect.

Circadian timing is a second consideration. Clock-gated expression of metabolic enzymes means that the same exposure at different times of day can be processed differently; the circadian framing is supported by the REV-ERB work above, including the ARPE-19 phagocytosis rhythm study (PMID 37027909). Species differences matter too: metabolite patterns characterised in camel liver homogenate and a fungal model are reference tools, and the study generated them for analytical purposes rather than as a human metabolism claim (PMID 42530886).

Other REV-ERB Agonists Are Not Interchangeable

Compounds that share a receptor target do not share pharmacokinetics. A 2026 study reported that STL1267, a distinct REV-ERB agonist, inhibited myofibroblast differentiation in a TGFβ1-driven human lung fibroblast model (PMID 41512274). That work describes a different molecule in an in vitro system; its results say nothing about how long SR9009 persists in a living organism.

Tolerability and Safety Signals: What Studies Report

No verified paper on this page reported adverse events in humans taking SR9009, because none of them administered it to humans. The nearest safety-adjacent material is mechanistic: the 2025 review examined how REV-ERBα modifiers influence cyclophosphamide-induced hepatotoxicity, indicating that REV-ERB pathway manipulation intersects with liver injury biology (PMID 40211567). Animal and cell work reported effects on immune clearance (PMID 31379019) and cardiac remodelling-linked NR1D1 expression (PMID 34057573), which locates REV-ERB signalling in systems where unintended consequences would be relevant — but these are mechanism reports, not safety datasets. The honest summary is that the human safety and pharmacokinetic profile of SR9009 is uncharacterised in this literature.

Putting the Evidence in Order

1. No verified study here reported an SR9009 half-life in any species.
2. Metabolite identity has been characterised analytically for anti-doping detection (PMID 42530886).
3. Routine drug panels do not include SR9009 as an analyte; dedicated LC-HRMS methods are the relevant tool (PMID 42530886).
4. REV-ERB biology operates on circadian and transcriptional timescales, so effect duration and drug persistence are separate measurements (PMID 37027909).
5. Liver status is the clearance variable with the clearest conceptual link in the reviewed material (PMID 40211567).

Background on the receptor target and the wider research base is collected at the SR9009 overview. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or compound.

References

• LC-HRMS-Based Metabolic Profiling of the REV-ERB Agonist SR9009 in Camel Liver Homogenate and Cunninghamella elegans for Anti-Doping Analysis (Rapid Communications in Mass Spectrometry, 2026)
• Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers (Expert Opinion on Drug Metabolism & Toxicology, 2025)
• STL1267 inhibits myofibroblast differentiation in a TGFβ1-driven human lung fibroblast model (American Journal of Physiology: Cell Physiology, 2026)
• Senescence-induced alteration of circadian phagocytic activity of retinal pigment epithelium cell line ARPE-19 (Biochemical and Biophysical Research Communications, 2023)
• Elimination of endogenous high molecular weight FGF2 prevents pressure-overload-induced systolic dysfunction, linked to increased FGFR1 activity and NR1D1 expression (Cell and Tissue Research, 2021)
• Frontline Science: Rev-Erbα links blue light with enhanced bacterial clearance and improved survival in murine Klebsiella pneumoniae pneumonia (Journal of Leukocyte Biology, 2020)